MX339116B - Tratamiento de esclerosis tuberosa. - Google Patents

Tratamiento de esclerosis tuberosa.

Info

Publication number
MX339116B
MX339116B MX2013000627A MX2013000627A MX339116B MX 339116 B MX339116 B MX 339116B MX 2013000627 A MX2013000627 A MX 2013000627A MX 2013000627 A MX2013000627 A MX 2013000627A MX 339116 B MX339116 B MX 339116B
Authority
MX
Mexico
Prior art keywords
tuberous sclerosis
sclerosis treatment
treatment
tuberous
rapamycin derivatives
Prior art date
Application number
MX2013000627A
Other languages
English (en)
Inventor
Heidi Lane
David Lebwohl
William Berg
John Benedetto
Ingrid Elmroth
William Sellers
Michael Stumm
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37944274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX339116(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0602123A external-priority patent/GB0602123D0/en
Priority claimed from GB0603568A external-priority patent/GB0603568D0/en
Priority claimed from GB0604593A external-priority patent/GB0604593D0/en
Priority claimed from GB0605760A external-priority patent/GB0605760D0/en
Priority claimed from GB0609698A external-priority patent/GB0609698D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX339116B publication Critical patent/MX339116B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Derivados de rapamicina para utilizarse en el tratamiento de trastornos neurocutáneos.
MX2013000627A 2006-02-02 2007-01-31 Tratamiento de esclerosis tuberosa. MX339116B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0602123A GB0602123D0 (en) 2006-02-02 2006-02-02 Organic compounds
GB0603568A GB0603568D0 (en) 2006-02-22 2006-02-22 Organic compounds
GB0604593A GB0604593D0 (en) 2006-03-07 2006-03-07 Organic compounds
GB0605760A GB0605760D0 (en) 2006-03-22 2006-03-22 Organic compounds
GB0609698A GB0609698D0 (en) 2006-05-16 2006-05-16 Organic compounds
PCT/EP2007/000818 WO2007088034A2 (en) 2006-02-02 2007-01-31 Tuberous sclerosis treatment

Publications (1)

Publication Number Publication Date
MX339116B true MX339116B (es) 2016-05-12

Family

ID=37944274

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000627A MX339116B (es) 2006-02-02 2007-01-31 Tratamiento de esclerosis tuberosa.

Country Status (21)

Country Link
US (1) US20100305150A1 (es)
EP (2) EP1983984B1 (es)
JP (2) JP5639743B2 (es)
KR (2) KR20140016439A (es)
CN (1) CN104000818B (es)
AU (1) AU2007211613C1 (es)
BR (1) BRPI0707684B1 (es)
CA (1) CA2637255C (es)
CY (1) CY1120741T1 (es)
DK (1) DK1983984T3 (es)
ES (1) ES2672627T3 (es)
HK (1) HK1251156A1 (es)
HU (1) HUE037890T2 (es)
LT (1) LT1983984T (es)
MX (1) MX339116B (es)
PL (1) PL1983984T3 (es)
PT (1) PT1983984T (es)
RU (1) RU2473343C2 (es)
SI (1) SI1983984T1 (es)
TR (1) TR201807065T4 (es)
WO (1) WO2007088034A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2637255C (en) 2006-02-02 2018-06-12 Novartis Ag 40-o-(2-hydroxyethyl)-rapamycin for treating tuberous sclerosis disorders
WO2012047587A2 (en) * 2010-09-27 2012-04-12 Serrata, Llc Mdm2 inhibitors for treatment of ocular conditions
AU2012211809A1 (en) * 2011-01-31 2013-09-05 Osaka University Externally-used drug for treating skin disorder and method for producing same
WO2013074583A1 (en) * 2011-11-14 2013-05-23 The Broad Institute, Inc. Treatment and prognosis of lymphangioleiomyomatosis
CN105163735B (zh) 2013-02-01 2018-12-11 格力尔罗格克斯股份有限公司 用于治疗神经退行性疾病和其他疾病的组合物和方法
US9925202B2 (en) 2013-03-04 2018-03-27 Brigham And Women's Hospital, Inc. Treatment of lymphangioleiomyomatosis
HUE048755T2 (hu) 2013-03-19 2020-08-28 Univ Pompeu Fabra A CB1 kannabinoidreceptor antagonistái neuronális dendritikus abnormalitásokhoz kapcsolódó betegségek kezelésében történõ alkalmazásra
CN113768881A (zh) 2013-10-08 2021-12-10 人工智能治疗公司 用于治疗淋巴管平滑肌瘤病的雷帕霉素
WO2015069217A1 (en) * 2013-11-05 2015-05-14 Baylor College Of Medicine Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis
KR20160120739A (ko) 2014-02-11 2016-10-18 램 테라퓨틱스, 인코포레이티드 림프관평활근종증의 치료를 위한 라파마이신
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
RU2718583C2 (ru) 2014-04-04 2020-04-08 ЭйАй ТЕРАПЬЮТИКС, ИНК. Рапамицин-содержащая композиция, вводимая путем ингаляции для лечения возрастных заболеваний
WO2016057712A1 (en) 2014-10-07 2016-04-14 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
CN104490873A (zh) * 2014-11-25 2015-04-08 邹丽萍 一种治疗儿童结节性硬化症的药物
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
JP6541124B2 (ja) 2015-03-23 2019-07-10 国立大学法人大阪大学 びまん性神経線維腫用の外用薬
US20190167649A1 (en) 2016-08-10 2019-06-06 The Board Of Regents Of The University Of Texas System Topical rapamycin therapy
MX2021010058A (es) 2019-02-20 2021-11-12 Ai Therapeutics Inc Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
DK0833828T3 (da) * 1995-06-09 2003-03-17 Novartis Ag Rapamycinderivater
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
EP2269603B1 (en) 2001-02-19 2015-05-20 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with exemestane
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
WO2004014222A2 (en) * 2002-08-12 2004-02-19 The Regents Of The University Of Michigan Diagnosis and treatment of tuberous sclerosis
US20050070567A1 (en) * 2002-08-12 2005-03-31 The Regents Of The University Of Michigan Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
US20040266811A1 (en) * 2002-11-08 2004-12-30 Weinstein David E. Methods for inducing regeneration, remyelination, and hypermyelination of nervous tissue
MXPA05008649A (es) * 2003-02-14 2005-11-23 Combinatorx Inc Terapia de combinacion para el tratamiento de desordenes inmunoinflamatorios.
ES2316995T3 (es) * 2003-07-08 2009-04-16 Novartis Ag Uso de rapamicina y derivados de rapamicida para el tratamiento de la perdida osea.
WO2005016252A2 (en) * 2003-07-11 2005-02-24 Ariad Gene Therapeutics, Inc. Phosphorus-containing macrocycles
GB0327840D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
US20060160837A1 (en) * 2004-12-29 2006-07-20 The Brigham And Women's Hospital, Inc. Rapamycin compounds in the treatment of neurofibromatosis type 1
CA2637255C (en) 2006-02-02 2018-06-12 Novartis Ag 40-o-(2-hydroxyethyl)-rapamycin for treating tuberous sclerosis disorders

Also Published As

Publication number Publication date
CA2637255C (en) 2018-06-12
SI1983984T1 (en) 2018-06-29
JP2013224298A (ja) 2013-10-31
HK1251156A1 (zh) 2019-01-25
CA2637255A1 (en) 2007-08-09
WO2007088034A2 (en) 2007-08-09
DK1983984T3 (en) 2018-06-14
PT1983984T (pt) 2018-06-14
EP1983984A2 (en) 2008-10-29
CN104000818A (zh) 2014-08-27
HUE037890T2 (hu) 2018-09-28
CY1120741T1 (el) 2019-12-11
EP3348265A1 (en) 2018-07-18
ES2672627T3 (es) 2018-06-15
AU2007211613A1 (en) 2007-08-09
AU2007211613C1 (en) 2018-01-04
WO2007088034A3 (en) 2007-11-01
JP5639743B2 (ja) 2014-12-10
TR201807065T4 (tr) 2018-06-21
KR20080090493A (ko) 2008-10-08
RU2008135131A (ru) 2010-03-10
BRPI0707684B1 (pt) 2021-10-13
CN104000818B (zh) 2017-11-21
RU2473343C2 (ru) 2013-01-27
PL1983984T3 (pl) 2018-08-31
US20100305150A1 (en) 2010-12-02
BRPI0707684A2 (pt) 2011-05-10
LT1983984T (lt) 2018-06-11
EP1983984B1 (en) 2018-03-07
AU2007211613B2 (en) 2011-04-28
BRPI0707684A8 (pt) 2017-12-26
JP2009525294A (ja) 2009-07-09
KR20140016439A (ko) 2014-02-07

Similar Documents

Publication Publication Date Title
MX339116B (es) Tratamiento de esclerosis tuberosa.
HK1134679A1 (zh) 用於治療感染的組合物和方法
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
IL193080A0 (en) Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
HK1139861A1 (en) Pde7 inhibitors for use in the treatment of movement disorders 7(pde7)
HK1130208A1 (en) Alpha-msh derivatives for the treatment of photodermatoses -msh
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
HK1247943A1 (zh) 發育相關疾病的治療
HK1129585A1 (en) Compound for use in the treatment of valvular stenosis
IL205578A0 (en) Aldh-2 inhibitors in the treatment of psychiatric disorders
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
WO2008002855A8 (en) Methods for the treatment of wounds
HK1134032A1 (en) New combination for use in the treatment of inflammatory disorders
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
EP2023894A4 (en) FIXED COMBINATION DOSAGE FOR TREATING MIGRAINE
EP2039342A4 (en) MEANS FOR MAINTAINING THE HARDENING TISSUE STRUCTURE
AU2016204522A1 (en) Tuberous Sclerosis treatment
PH12014500538A1 (en) Methods and compositions for treating leukemia
EP2056811B8 (en) Modafinil-based treatment for premature ejaculation
ZA200806180B (en) Benzoisoindole derivatives for the treatment of pain
AU2007906680A0 (en) Methods and compositions for the treatment of phosphatase-related disorders
AU2007901213A0 (en) Compositions for the treatment of sexual dysfunction
AU2006906505A0 (en) Agent for the treatment of hormone-dependent disorders and uses thereof